2006PubMedRequires access

[Bisphosphonate therapy for osteoporosis and bone strength].

Hideaki Kishimoto

Open publisher page 2 citations

Abstract

Bisphosphonates are now the most widely used drugs for osteoporosis. When bisphosphonate is given, the response varies directly with the rate of bone turnover at baseline. In high turnover osteoporosis there could be a gain in bone mass, but it reach a plateau after 2 to 3 years. In normal or low turnover osteoporosis bone mass is stabilized or slightly increased. The best indication of bisphosphonate use for osteoporosis is high turnover. In high turnover osteoporosis bisphosphonate therapy is effective in increasing the stiffness and the toughness (bone strength) by increasing the mean degree of mineralization of bone tissue through the prolongation of secondary mineralization. But the long-term use of bisphosphonate would result in highly mineralized bone and disturbed repair of microcracks by inhibition of bone remodeling. Intermittent use of bisphosphonate could be recommended to avoid the deterioration of bone quality.

About this research paper

What this paper is about

Bisphosphonates are now the most widely used drugs for osteoporosis. When bisphosphonate is given, the response varies directly with the rate of bone turnover at baseline. In high turnover osteoporosis there could be a gain in bone mass, but it reach a plateau after 2 to 3 years. In normal or low turnover osteoporosis bone mass is stabilized or slightly increased. The best indication of bisphosphonate use for osteoporosis is high turnover. In high turnover osteoporosis bisphosphonate therapy is effective in increasing the stiffness and the toughness (bone strength) by increasing the mean degree of mineralization of bone tissue through the prolongation of secondary mineralization. But the long-term use of bisphosphonate would result in highly mineralized bone and disturbed repair of microcracks by inhibition of bone remodeling. Intermittent use of bisphosphonate could be recommended to avoid the deterioration of bone quality.

Why it matters

OpenAlex reports 2 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Bisphosphonates are now the most widely used drugs for osteoporosis. When bisphosphonate is given, the response varies directly with the rate of bone turnover at baseline. In high turnover osteoporosis there could be a gain in bone mass, but it reach a plateau after 2 to 3 years. In normal or low turnover osteoporosis bone mass is stabilized or slightly increased. The best indication of bisphosphonate use for osteoporosis is high turnover. In high turnover osteoporosis bisphosphonate therapy is effective in increasing the stiffness and the toughness (bone strength) by increasing the mean degree of mineralization of bone tissue through the prolongation of secondary mineralization. But the long-term use of bisphosphonate would result in highly mineralized bone and disturbed repair of microcracks by inhibition of bone remodeling. Intermittent use of bisphosphonate could be recommended to avoid the deterioration of bone quality.

Key concepts: Bisphosphonate, Osteoporosis, Bone remodeling, Medicine, Dentistry, Internal medicine, Bone mass, Urology

Related papers

Back to paper searchBrowse research topicsOriginal source
[Bisphosphonate therapy for osteoporosis and bone strength]. — Research Paper | ScholarLens